COVID-19 Sürecinin İhmal Edilmiş Paraziter 
Hastalıklar Üzerine Etkisi

ulusan, özlem

doi:10.4274/tpd.galenos.2021.25744

COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi

Özlem ULUSAN BAĞCI (İzmir Katip Çelebi Üniversitesi, Atatürk Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Kliniği, İzmir, Türkiye)

Türkiye Parazitoloji Dergisi

1 0

Yıl: 2021 Cilt: 45 Sayı: 4 Sayfa Aralığı: 317 - 325 Metin Dili: Türkçe DOI: 10.4274/tpd.galenos.2021.25744 İndeks Tarihi: 25-05-2022

COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi

Öz:

Aralık 2019’da Çin’in Wuhan şehrinde başlayarak kısa sürede tüm dünyayı etkisi altına alan ve yaklaşık dört milyon kişinin ölümüne neden olan Koronavirüs hastalığı-2019 (COVID-19) hakkında kısa sürede çok sayıda araştırma yapılmıştır. Evrimsel süreci insanlık tarihi kadar eski olan parazitler sık görülen ve yüksek mortalite oranına sahip enfeksiyon etkenleri olmalarına rağmen çoğunlukla ihmal edilmektedir. Bununla birlikte son zamanlarda yapılan çalışmalar paraziter enfeksiyonların neden olduğu immünite değişikliğinin viral hastalıkların seyrini etkilediğini göstermektedir. Ciddi respiratuvar sendrom-koronavirüs-2 (SARSCoV-2) ve Plasmodium’un hücre içine girmek için CD147 reseptörünü ortak kullanması ve her iki etkenin de MHC ile sunulan antijenik determinantlarında benzerlikler olması nedeniyle; paraziter enfeksiyonlara karşı gelişen bağışıklığın, vücudu SARSCoV-2 enfeksiyonuna karşı koruyabildiği düşünülmekte olup, bu durum sıtmanın endemik olduğu ülkelerdeki düşük COVID-19 insidansının nedenini açıklayabilir. COVID-19 enfeksiyonunda mortaliteden sorumlu olan sitokin fırtınasına, immün sistemin Th1 yönünde aktifleşmesi neden olmaktadır. Diğer taraftan immün sistemi Th2 yönünde aktifleştiren helmint enfeksiyonları, sitokin fırtınasını engelleyerek mortaliteyi azaltabilir. COVID-19 ve parazitler arasındaki ilişki sadece immün sistem değişikliği ile sınırlı değildir. Pandeminin başından itibaren tüm ilginin COVID-19’a yönelmesi ile paraziter enfeksiyonlarla mücadelede duraksamaya gidilmesinin sıtma, leyşmanyazis, şistozomiyaz ve topraktan bulaşan helmintler gibi birçok etkenin insidansında artışa yol açacağı gösterilmiştir. Bu nedenle bir an önce tekrar mücadeleye kalındığı yerden ek önlemler alınarak devam edilmeli ve tüm dünyayı kapsayacak şekilde genişletilmelidir.

Anahtar Kelime:

Impact of the COVID-19 Duration on Neglected Parasitic Diseases

Öz:

The Coronavirus disease-2019 (COVID-19) pandemic, which started in Wuhan, China in December 2019, has affected the whole world and caused approximately four million deaths. Consequently, scientists have done a great deal of research in such a short time about the disease. Meanwhile, parasites, whose evolutionary process is as old as human history, are often underestimated despite their high prevalence and lethality. Recent studies; however, have shown that immunity changes caused by parasitic infections affect the course of viral diseases. For example, because severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and Plasmodium use a common CD147 receptor to enter the cell and have similarities in their MHC-presented antigenic determinants, scientists suggest that immunity against parasitic infections protects the body against SARS-CoV-2 infections. This could explain the low COVID-19 incidence in malaria-endemic countries. Additionally, the cytokine storm, which is responsible for mortality in COVID-19 infections, is caused by the activation of the immune system to Th1 way. On the other hand, helminth infections, which activate the immune system to Th2 way, can reduce mortality by preventing the cytokine storm. The relationship between COVID-19 and parasites is not limited to changes in the immune system changes. Studies have shown that the pause in the fight against parasitic infections due to the diversion of all attention toward COVID-19 since the beginning of the pandemic will lead to an increase in incidences of malaria, leishmaniasis, schistosomiasis, and soil-transmitted helminths. For this reason, efforts to mitigate this increase should be resumed as soon as possible by taking additional measures globally.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. WHO. Novel coronavirus – China. 2020. Available from: http://www. who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (Last accessed date: 19 Jan 2020).
2. WHO. Coronavirus disease (COVID-19) situation report-118. Available from: ho.int/docs/default-source/coronaviruse/situationreports/20200517-covid-19-sitrep-118.pdf?sfvrsn=21c0dafe_10 (Last accessed date: 17 May 2020).
3. WHO. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (Last accessed date: 5 Jun 2021).
4. Worldometer. COVID-19 Coronavirus Pandemic. Available from: https:// www.worldometers.info/coronavirus/. (Last accessed date: 4 Jun 2021).
5. Cox FE. History of human parasitology. Clin Microbiol Rev 2002; 15: 595- 612.
6. Ashford RW, Crewe W. The parasites of Homo sapiens. Liverpool: Liverpool School of Tropical Medicine; 1998.
7. COVID-19: WHO issues interim guidance for implementation of NTD programmes. Geneva: World Health Organization. Available from: https://www.who.int/neglected_diseases/news/COVID19-WHOinterim-guidance-implementation-NTD-programmes/en/ (Last accessed date: 27 Jul 2020)
8. Roychoudhury S, Das A, Sengupta P, Dutta S, Roychoudhury S, Choudhury AP, et al. Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. Int J Environ Res Public Health 2020; 17: 9411.
9. Walker PGT, Whittaker C, Watson O, Baguelin M, Ainslie KEC, Bhatia S, et al. Report 12: The Global Impact of COVID19 and Strategies for Mitigation and Suppression. Available from: https://www.imperial.ac.uk/ media/imperial-college/medicine/ mrc-gida/2020-03-26-COVID19- Report-12 (Last accessed date 11 Jun 2021).
10. United Nations Department of Economic and Social Affairs Population Division, 2019. World Population Prospects 2019. Available from: https:// population.un.org/wpp/DataQuery/. (Last accessed date: 20 April 2020).
11. Bucşan AN, Williamson KC. Setting the stage: The initial immune response to blood-stage parasites. Virulence 2020; 11: 88-103.
12. Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, et al. Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19? Am J Trop Med Hyg 2020; 103: 572-7.
13. Thompson MG, Breiman RF, Hamel MJ, Desai M, Emukule G, Khagayi S, et al. Influenza and malaria coinfection among young children in western Kenya, 2009-2011. J Infect Dis 2012; 206: 1674-84.
14. Lokken KL, Stull-Lane AR, Poels K, Tsolis RM. Malaria Parasite-Mediated Alteration of Macrophage Function and Increased Iron Availability Predispose to Disseminated Nontyphoidal Salmonella Infection. Infect Immun 2018; 86: e00301-18.
15. Harris NL, Loke P. Recent Advances in Type-2-Cell-Mediated Immunity: Insights from Helminth Infection. Immunity 2017; 47: 1024-36.
16. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020; 31: 961-4.
17. Siles-Lucas M, González-Miguel J, Geller R, Sanjuan R, Pérez-Arévalo J, Martínez-Moreno Á. Potential Influence of Helminth Molecules on COVID-19 Pathology. Trends Parasitol 2021; 37: 11-4.
18. Ssebambulidde K, Segawa I, Abuga KM, Nakate V, Kayiira A, Ellis J, et al. Parasites and their protection against COVID-19- Ecology or Immunology? doi: https://doi.org/10.1101/2020.05.11.20098053.
19. WHO. Schistosomiasis. Available from: https://www.who.int/news-room/ fact-sheets/detail/schistosomiasis. (Last accessed date: 5 July 2021).
20. STOLL NR. This wormy world. J Parasitol 1947; 33: 1-18.
21. Loker ES. This de-wormed world? J Parasitol 2013; 99: 933-42.
22. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545-602.
23. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci 2014; 369: 20130434.
24. Capela R, Moreira R, Lopes F. An Overview of Drug Resistance in Protozoal Diseases. Int J Mol Sci 2019; 20: 5748.
25. Hillyer JF. Parasites and Parasitology in this SARS-CoV-2, COVID-19 World: An American Society of Parasitologists Presidential Address. J Parasitol 2020; 106: 859-68.
26. COVID-19: WHO issues interim guidance for implementation of NTD programmes. Geneva: World Health Organization; 2020. Available from: https://www.who.int/neglected_diseases/news/COVID19-WHOinterim-guidance-implementation-NTD-programmes/en/ (last accessed date: 12 June 2021).
27. Prada JM, Stolk WA, Davis EL, Touloupou P, Sharma S, Muñoz J, et al. Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies. Trans R Soc Trop Med Hyg 2021; 115: 261-8.
28. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
29. WHO. World Malaria Report 2019. World Health Organization. Available online: https://www.who.int/publications/i/item/9789241565721 (accessed on 16 July 2020).
30. World Malaria Day. Available from: https://endmalaria.org/ worldmalariaday2021. (Last accessed date:6 July 2021).
31. Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC. Malaria. Nat Rev Dis Primers 2017; 3: 17050.
32. WHO. The Potential Impact of Health Service Disruptions on the Burden of Malaria: A Modelling Analysis for Countries in Sub-Saharan Africa. Available from: https://www.who.int/publicationsdetail/the-potentialimpact-of-health-service-disruptions-onthe-burden-of-malaria. (Last accessed date: 21 May 2020).
33. Tailoring malaria interventions in the COVID-19 response. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
34. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available from:https://covid19.who.int/?gclid=CjwKC AiA x K v B R B d E i w A y d 4 0 N 0 H c T r W K X d 6 9 t 0 Q h M o M F 5 E j A EgeHrwlOqAHXOqdaEAZ8gkqvaurtRoChiIQAvDBwE (Last accessed date: 29 December 2020).
35. Sargin G, Yavaşoğlu Sİ, Yavasoglu I. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria? Med Hypotheses 2020; 140: 109756.
36. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther 2020; 5: 283.
37. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011; 480: 534-7.
38. Kalungi A, Kinyanda E, Akena DH, Kaleebu P, Bisangwa IM. Less Severe Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of Plasmodium falciparum Infection Be Protective? Front Immunol 2021; 12: 565625.
39. Iesa MAM, Osman MEM, Hassan MA, Dirar AIA, Abuzeid N, Mancuso JJ, et al. SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New Microbes New Infect 2020; 38: 100817.
40. Bian H, Zheng ZH, Wei D, Wen A, Zhang Z, Lian JQ, et al. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Transduct Target Ther 2021; 6: 194.
41. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5: 33.
42. Lv M, Miao J, Zhao P, Luo X, Han Q, Wu Z, et al. CD147-mediated chemotaxis of CD4+ CD161+ T cells may contribute to local inflammation in rheumatoid arthritis. Clin Rheumatol 2018; 37: 59-66.
43. WHO 2019. Leishmaniasis. Available from: http://www.who.int/ mediacentre/factsheets/fs375/en/ (Last accessed date: 20 Feb 2017).
44. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res 2017; 6: 750.
45. World Health Organization Regional Office for South-East Asia. Process of validation of elimination of Kala-azar as a public health problem in South-East Asia. New Delhi: World Health Organization Regional Office for South-East Asia; 2016.
46. Le Rutte EA, Coffeng LE, Muñoz J, de Vlas SJ. Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India. Trans R Soc Trop Med Hyg 2021; 115: 229-35.
47. Miotti AM, Patacca A, Grosso C, Cristini F. COVID-19 in a patient with visceral leishmaniasis. J Infect Dis Ther 2020; 8: 430.
48. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current State of the Science. Immunity 2020; 52: 910-41.
49. Conceição-Silva F, Morgado FN. Leishmania Spp-Host Interaction: There Is Always an Onset, but Is There an End? Front Cell Infect Microbiol 2019; 9: 330.
50. Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al. Strongyloidiasis--the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg 2009; 103: 967-72.
51. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 2013; 13: 78.
52. Lier AJ, Tuan JJ, Davis MW, Paulson N, McManus D, Campbell S, et al. Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19. Am J Trop Med Hyg 2020; 103: 1590-2.
53. Ming DK, Armstrong M, Lowe P, Chiodini PL, Doherty JF, Whitty CJM, et al. Clinical and Diagnostic Features of 413 Patients Treated for Imported Strongyloidiasis at the Hospital for Tropical Diseases, London. Am J Trop Med Hyg 2019; 101: 428-31.
54. De Wilton A, Nabarro LE, Godbole GS, Chiodini PL, Boyd A, Woods K. Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19. Travel Med Infect Dis 2021; 40: 101981.
55. World Health Organization. Guideline: Preventive Chemotherapy to Control Soil-Transmitted Helminth Infections in at-Risk Population Groups. World Health Organization, 2017. Available from: https://apps. who.int/iris/bitstream/handle/10665/258983/ 9789241550116-eng.pdf (Last accessed date: 3 Jun 2019).
56. World Health Organization. 2030 Targets for Soil-Transmitted Helminthiases Control Programmes. 2020. Available from: https: //apps. who.int/iris/bitstream/handle/ 10665/330611/9789240000315-eng. pdf (Last accessed date: July 2019).
57. Malizia V, Giardina F, Vegvari C, Bajaj S, McRae-McKee K, Anderson RM, et al. Modelling the impact of COVID-19-related control programme interruptions on progress towards the WHO 2030 target for soiltransmitted helminths. Trans R Soc Trop Med Hyg 2021; 115: 253-60.
58. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.
59. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1260-1344.
60. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers 2018; 4: 13.
61. WHO. Schistosomiasis Progress Report. 2001–2011 and Strategic Plan 2012–2020. World Health Organization; Geneva: 2012.
62. Kura K, Ayabina D, Toor J, Hollingsworth TD, Anderson RM. Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies. Trans R Soc Trop Med Hyg 2021; 115: 236-44.
63. Huang YS, Vanlandingham DL, Bilyeu AN, Sharp HM, Hettenbach SM, Higgs S. SARS-CoV-2 failure to infect or replicate in mosquitoes: an extreme challenge. Sci Rep 2020; 10: 11915.
64. Centers for Disease Control and Prevention. International Catalog of Arboviruses. In: Prevention CfDCa, editor. Atlanta, GA: Center for Disease Control and Prevention, 1985.
65. Higgs S, Schneider BS, Vanlandingham DL, Klingler KA, Gould EA. Nonviremic transmission of West Nile virus. Proc Natl Acad Sci U S A 2005; 102: 8871-4.
66. Balaraman V, Drolet BS, Mitzel DN, Wilson WC, Owens J, Gaudreault NN, et al. Mechanical transmission of SARS-CoV-2 by house flies. Parasit Vectors 2021; 14: 214.
67. White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med 2020; 17: e1003252.
68. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264-8.
69. Skinner TS, Manning LS, Johnston WA, Davis TM. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol 1996; 26: 519-25.
70. Schilling WH, White NJ. Does hydroxychloroquine still have any role in the COVID-19 pandemic? Expert Opin Pharmacother 2021; 22: 1257-66.
71. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384: 693-704.
72. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511.
73. Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 13-28.
74. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo) 2020; 73: 593-602.
75. Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep 2021; 73: 736-49.
76. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, et al. Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPSinduced survival in mice. Inflamm Res 2008; 57: 524-9.
77. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787.
78. Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One 2020; 15: e0242184.
79. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42: 1122-33.
80. Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from a pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment 2020; 34: 469-74.

APA	ulusan ö (2021). COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. , 317 - 325. 10.4274/tpd.galenos.2021.25744
Chicago	ulusan özlem COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. (2021): 317 - 325. 10.4274/tpd.galenos.2021.25744
MLA	ulusan özlem COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. , 2021, ss.317 - 325. 10.4274/tpd.galenos.2021.25744
AMA	ulusan ö COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. . 2021; 317 - 325. 10.4274/tpd.galenos.2021.25744
Vancouver	ulusan ö COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. . 2021; 317 - 325. 10.4274/tpd.galenos.2021.25744
IEEE	ulusan ö "COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi." , ss.317 - 325, 2021. 10.4274/tpd.galenos.2021.25744
ISNAD	ulusan, özlem. "COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi". (2021), 317-325. https://doi.org/10.4274/tpd.galenos.2021.25744

APA	ulusan ö (2021). COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. Türkiye Parazitoloji Dergisi, 45(4), 317 - 325. 10.4274/tpd.galenos.2021.25744
Chicago	ulusan özlem COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. Türkiye Parazitoloji Dergisi 45, no.4 (2021): 317 - 325. 10.4274/tpd.galenos.2021.25744
MLA	ulusan özlem COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. Türkiye Parazitoloji Dergisi, vol.45, no.4, 2021, ss.317 - 325. 10.4274/tpd.galenos.2021.25744
AMA	ulusan ö COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. Türkiye Parazitoloji Dergisi. 2021; 45(4): 317 - 325. 10.4274/tpd.galenos.2021.25744
Vancouver	ulusan ö COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi. Türkiye Parazitoloji Dergisi. 2021; 45(4): 317 - 325. 10.4274/tpd.galenos.2021.25744
IEEE	ulusan ö "COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi." Türkiye Parazitoloji Dergisi, 45, ss.317 - 325, 2021. 10.4274/tpd.galenos.2021.25744
ISNAD	ulusan, özlem. "COVID-19 Sürecinin İhmal Edilmiş Paraziter Hastalıklar Üzerine Etkisi". Türkiye Parazitoloji Dergisi 45/4 (2021), 317-325. https://doi.org/10.4274/tpd.galenos.2021.25744